JP2002528420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528420A5 JP2002528420A5 JP2000578021A JP2000578021A JP2002528420A5 JP 2002528420 A5 JP2002528420 A5 JP 2002528420A5 JP 2000578021 A JP2000578021 A JP 2000578021A JP 2000578021 A JP2000578021 A JP 2000578021A JP 2002528420 A5 JP2002528420 A5 JP 2002528420A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- polypeptide
- polynucleotide
- kit
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 28
- 108091033319 polynucleotide Proteins 0.000 description 28
- 239000002157 polynucleotide Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 208000037803 restenosis Diseases 0.000 description 20
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 19
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 description 19
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 17
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10558798P | 1998-10-26 | 1998-10-26 | |
| US60/105,587 | 1998-10-26 | ||
| PCT/US1999/024054 WO2000024412A2 (en) | 1998-10-26 | 1999-10-26 | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011015549A Division JP5231587B2 (ja) | 1998-10-26 | 2011-01-27 | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002528420A JP2002528420A (ja) | 2002-09-03 |
| JP2002528420A5 true JP2002528420A5 (https=) | 2007-02-22 |
| JP4769929B2 JP4769929B2 (ja) | 2011-09-07 |
Family
ID=22306672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578021A Expired - Fee Related JP4769929B2 (ja) | 1998-10-26 | 1999-10-26 | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 |
| JP2011015549A Expired - Fee Related JP5231587B2 (ja) | 1998-10-26 | 2011-01-27 | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011015549A Expired - Fee Related JP5231587B2 (ja) | 1998-10-26 | 2011-01-27 | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1126870B1 (https=) |
| JP (2) | JP4769929B2 (https=) |
| CN (1) | CN1338943A (https=) |
| AT (1) | ATE275417T1 (https=) |
| AU (1) | AU768330B2 (https=) |
| CA (1) | CA2340593C (https=) |
| DE (1) | DE69920031T2 (https=) |
| ES (1) | ES2229788T3 (https=) |
| NO (1) | NO20012017L (https=) |
| NZ (1) | NZ510121A (https=) |
| PT (1) | PT1126870E (https=) |
| WO (1) | WO2000024412A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
| AU3988401A (en) | 2000-02-25 | 2001-09-03 | Ludwig Inst Cancer Res | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| US7201898B2 (en) * | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| TWI257307B (en) | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
| MXPA02003434A (es) | 2000-08-04 | 2002-09-02 | Human Genome Sciences Inc | Factor de crecimiento endotelial vascular 2. |
| ATE481097T1 (de) * | 2001-01-16 | 2010-10-15 | Vascular Therapies Llc | Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate |
| CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| FI20010898A0 (fi) * | 2001-04-30 | 2001-04-30 | Ylae Herttuala Seppo | Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi |
| GB0120690D0 (en) | 2001-08-24 | 2001-10-17 | Novartis Ag | Organic compounds |
| AU2003224587A1 (en) * | 2002-04-30 | 2003-11-17 | Fit Biotech Oyj Plc | Medical device |
| PL195457B1 (pl) * | 2002-08-05 | 2007-09-28 | Zaklady Farm Polpharma Sa | Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie |
| WO2005039556A1 (ja) * | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬 |
| WO2005089822A1 (ja) * | 2004-03-18 | 2005-09-29 | Kensuke Egashira | 薬剤・遺伝子溶出型ステント |
| EP1919944B1 (en) | 2005-08-15 | 2011-03-23 | Vegenics Pty Ltd | Modified vegf and pdgf with improved angiogenic properties |
| CN101563102B (zh) | 2006-09-22 | 2014-12-17 | 德克萨斯系统大学董事会 | 治疗内皮功能障碍的方法 |
| KR20100129295A (ko) | 2008-02-19 | 2010-12-08 | 셀라돈 코포레이션 | 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물 |
| CN101361988B (zh) * | 2008-09-12 | 2011-12-21 | 西南交通大学 | 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法 |
| WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
| CN108640994A (zh) * | 2018-06-28 | 2018-10-12 | 浙江众意生物科技有限公司 | 一种vegf-c单克隆抗体及试剂盒 |
| IL286675B2 (en) * | 2019-03-29 | 2026-02-01 | Abiomed Inc | Systems and methods for left ventricular unloading in biological therapy or vector gene therapy |
| CN119454907A (zh) * | 2025-01-09 | 2025-02-18 | 浙江大学 | Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
| WO1998007832A1 (en) * | 1996-08-23 | 1998-02-26 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
| US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| EP0977854A2 (en) * | 1997-04-25 | 2000-02-09 | Collateral Therapeutics | Truncated vegf-related proteins |
-
1999
- 1999-10-26 EP EP99956559A patent/EP1126870B1/en not_active Expired - Lifetime
- 1999-10-26 WO PCT/US1999/024054 patent/WO2000024412A2/en not_active Ceased
- 1999-10-26 DE DE69920031T patent/DE69920031T2/de not_active Expired - Lifetime
- 1999-10-26 CN CN99812544A patent/CN1338943A/zh active Pending
- 1999-10-26 CA CA2340593A patent/CA2340593C/en not_active Expired - Fee Related
- 1999-10-26 AU AU13147/00A patent/AU768330B2/en not_active Ceased
- 1999-10-26 JP JP2000578021A patent/JP4769929B2/ja not_active Expired - Fee Related
- 1999-10-26 AT AT99956559T patent/ATE275417T1/de not_active IP Right Cessation
- 1999-10-26 PT PT99956559T patent/PT1126870E/pt unknown
- 1999-10-26 NZ NZ510121A patent/NZ510121A/xx unknown
- 1999-10-26 ES ES99956559T patent/ES2229788T3/es not_active Expired - Lifetime
-
2001
- 2001-04-24 NO NO20012017A patent/NO20012017L/no unknown
-
2011
- 2011-01-27 JP JP2011015549A patent/JP5231587B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528420A5 (https=) | ||
| JP5231587B2 (ja) | Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防 | |
| US8455453B2 (en) | Use of VEGF-D gene to prevent restenosis | |
| EP0741785B1 (en) | Methods and compositions for stimulating bone cells | |
| Taddei et al. | Inhibitory effect of full-length human endostatin on in vitro angiogenesis | |
| US5693607A (en) | Uses of TGF-β receptor fragment as a therapeutic agent | |
| ES2242227T3 (es) | Nuevo factor de tipo vegf. | |
| EP2234628B1 (en) | Compositions and methods of promoting wound healing | |
| US20090291891A1 (en) | VEGF variant that lacks VEGFR-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis | |
| JP2004502739A5 (https=) | ||
| KR970707141A (ko) | 종양 괴사 인자-감마(Tumor necrosis factor-gamma) | |
| JP2005036007A (ja) | トロンビン由来ペプチドを使用した治療法 | |
| US20080261888A1 (en) | Antibodies to PDGF-D | |
| Chamberlain | Transforming Growth Factor‐β: A Promising Target for Anti‐Stenosis Therapy | |
| US20030129214A1 (en) | Methods of enhancing the biocompatibility of an implantable medical device | |
| CN112190709A (zh) | 基质细胞蛋白ccn5组合物及其应用 | |
| JP4205592B2 (ja) | 心臓組織修復を促進するためのトロンビン由来ペプチド | |
| EP1568375A1 (en) | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis | |
| HUP0003831A2 (hu) | Szövetfaktor alkalmazása véredényképződés befolyásolására | |
| WO2007089780A9 (en) | Bmx/etk tyrosine kinase gene therapy materials and methods | |
| CN1926151A (zh) | 治疗或预防细胞外基质积聚 | |
| AU2004201020A1 (en) | Use of VEGF-C or VEGF-D Gene or Protein to Prevent Restenosis | |
| MXPA06009977A (en) | Treating or preventing extracellular matrix build-up | |
| Barry | Local device-based drug delivery for the treatment of vascular disease |